Publications and conferences
• Over 200 peer-reviewed publications (most recent publications at end)• Written many original articles, case reports and book chapters.
• Edited Book: Cardiology in Practice by Clive Handler• Associate Editor, Pulmonary Circulation• Editor for Rheumatology, Arthritis and Rheumatism, Eur Resp J, Lupus, Arthritis & Rheumatism, Hematologia, Pulmonary Circulation, Lancet & Thorax• Editor for Remedica (2010 – 2014)• Organised many conferences both nationally and internationally• Lectured both nationally and internationally• Gräf S, Haimel M, Bleda M, H…Coghlan G, et al. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat Commun. 2018 (ePub)• Coghlan JG, Wolf M, Distler O, Denton CP, Doelberg M, Harutyunova S, Marra AM, Benjamin N, Fischer C, Grünig E. Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. Eur Respir J. 2018 (ePub)• Dawson A, Reddecliffe S, Coghlan C, Schreiber BE, Coghlan JG. Safety and feasibility audit of a home-based drug-transitioning approach for patients with pulmonary arterial hypertension: an observational study. Eur J Cardiovasc Nurs. 2018 (ePub)• Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Gaine S. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. Am J Cardiovasc Drugs. 2018 Feb;18(1):37-47.• Mihai C, Antic M, Dobrota R, Bonderman D, Chadha-Boreham H, Coghlan JG, Denton CP, Doelberg M, Grünig E, Khanna D, McLaughlin VV, Müller-Ladner U, Pope JE, Rosenberg DM, Seibold JR, Vonk MC, Distler O. Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. Ann Rheum Dis. 2018 Jan;77(1):128-132• Coghlan JG, Denton C. Aggressive combination therapy for the treatment of scleroderma associated pulmonary Hypertension. JSRD 2018, Vol. 3(1) 30–38• Hadinnapola C, Bleda M, Haimel M, Screaton N, Swift A, Dorfmüller P, Preston SD, Southwood M, Hernandez-Sanchez J, Martin J, Treacy C, Yates K, Bogaard H, Church C, Coghlan G, Condliffe R, Corris PA, Gibbs S, Girerd B, Holden S, Humbert M, Kiely DG, Lawrie A, Machado R, MacKenzie Ross R, Moledina S, Montani D, Newnham M, Peacock A, Pepke-Zaba J, Rayner-Matthews P, Shamardina O, Soubrier F, Southgate L, Suntharalingam J, Toshner M, Trembath R, Noordegraaf AV, Wilkins MR, Wort SJ, Wharton J; NIHR BioResource–Rare Diseases Consortium; UK National Cohort Study of Idiopathic and Heritable PAH, Gräf S, Morrell NW. Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. Circulation. 2017 Nov 21;136(21):2022-2033. doi: 10.1161/CIRCULATIONAHA.117.028351. Epub 2017• Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galiè N, Ghofrani HA, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Hoeper MM. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017 Aug 17;50(2). pii: 1602493. doi: 10.1183/13993003.02493-2016• Schwaiger JP, Loder CD, Dobarro D, Kaier T, Reddecliffe S, Schreiber BE, Handler C, Denton CP, Coghlan JG. Optical coherence tomography evaluation of pulmonary arterial vasculopathy in Systemic Sclerosis. Sci Rep. 2017 Feb 24;7:43304.• Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION investigators.. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2017 Jul;76(7):1219-1227• Humbert M, Coghlan JG, Ghofrani HA, Grimminger F, He JG, Riemekasten G, Vizza CD, Boeckenhoff A, Meier C, de Oliveira Pena J, Denton CP. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis. 2017 Feb;76(2):422-426.• Coghlan JG, Schreiber BS, D’Cruz D. The heart in rheumatic disease. Chapter 35. Hochberg’s Rheumatology 6th Edition• Gräf S, Haimel M, Bleda M, H…Coghlan G, et al. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat Commun. 2018 (ePub)• Vanezis AP, Arnold JR, Rodrigo G, Lai FY, Debiec R, Nazir S, Khan JN, Ng LL, Chitkara K, CoghlanJG, Hetherington SL, McCann GP, Samani NJ. Daily remote ischaemic conditioning following acute myocardial infarction: a randomised controlled trial. Heart. 2018 May 10. pii: heartjnl-2018-313091.• Ito Y, Carss KJ, Duarte ST, et al; NIHR BioResource (Coghlan G); Care4Rare Canada Consortium, Boycott KM, Kernohan KD, Dyack S, Raymond FL. De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures. Am J Hum Genet. 2018 Jul 5;103(1):144-153.• Hobbs AJ, Moyes AJ, Baliga RS, Ghedia D, Ochiel R, Sylvestre Y, Doré CJ, Chowdhury K, Maclagan K, Quartly HL, Sofat R, Smit A, Schreiber BE, Coghlan GJ, MacAllister RJ. Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Br J Pharmacol. 2019 May;176(9):1251-1267• Sofianopoulou E, Kaptoge S, Gräf S, .. Coghlan G, … Morrell NW. Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension: A United Kingdom cohort study analysis. Eur Respir J. 2019 Mar 28. pii: 1801429.• Bunclark K, Newnham M, Chiu YD, Ruggiero A, Villar SS, Cannon JE, Coghlan G, Corris PA, Howard L, Jenkins D, Johnson M, Kiely DG, Ng C, Screaton N, Sheares K, Taboada D, Tsui S, Wort SJ, Pepke-Zaba J, Toshner M. A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. J Thromb Haemost. 2019 Sep 26. doi: 10.1111/jth.14649• Pan Z, Marra AM, Benjamin N, Eichstaedt CA, Blank N, Bossone E, Cittadini A, Coghlan G, Denton CP, Distler O, Egenlauf B, Fischer C, Harutyunova S, Xanthouli P, Lorenz HM, Grünig E. Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). Arthritis Res Ther. 2019 Oct 26;21(1):217. doi: 10.1186/s13075-019-1981-0.• Hodgson J, Swietlik EM, Salmon RM, … Coghlan G, … Morrell NW. Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2019 Oct 29. doi: 10.1164/rccm.201906-1141OC.• McLaughlin VV, Channick R, De Marco T, Farber HW, Gaine S, Galié N, Krasuski RA, Preston I, Souza R, Coghlan JG, Frantz RP, Hemnes A, Kim NH, Lang IM, Langleben D, Li M, Sitbon O, Tapson V, Frost A. Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. Chest. 2019 Nov 16. pii: S0012-3692(19)34214-X.• Kirresh A, Coghlan G, Candilio L. COVID-19 infection and high intracoronary thrombus burden. Cardiovasc Revasc Med. 2020 Jul 30:S1553-8389(20)30459-0. doi: 10.1016/j.carrev.2020.07.032• Hoeper MM, Pausch C, Grünig E, ..., Coghlan G, ... Held M. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. J Heart Lung Transplant. 2020 Sep 30:S1053-2498(20)31758-7. doi: 10.1016/j.healun.2020.09.011.• Sofianopoulou E, Church C, Coghlan G, et al. Deprivation and prognosis in patients with pulmonary arterial hypertension: missing the effect of deprivation on a rare disease? Eur Respir J. 2020 Aug 13;56(2):1902334. doi: 10.1183/13993003.02334-2019• Hodgson J, Swietlik EM, Salmon RM, ... Coghlan G, ... Morrell NW. Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2020 Mar 1;201(5):575-585.• Bunclark K, Newnham M, Chiu YD, ... Coghlan G, ... Toshner M. A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. J Thromb Haemost. 2020 Jan;18(1):114-122.• Lewis RA, Armstrong I, Bergbaum C, ...Coghlan JG, ...Toshner MR, Wanjiku I, Wort SJ, Yorke J, Condliffe R. EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease- associated pulmonary arterial hypertension: results from a UK multi-centre study. Eur Respir J. 2020 Jul 6:2000124.• Rhodes CJ, Otero-Núñez P, Wharton J, S...Coghlan JG, ... Wilkins MR. Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. Am J Respir Crit Care Med. 2020 Aug 15;202(4):586-594.• Peacock AJ, Ling Y, Johnson MK, Kiely DG, ... Coghlan JG, ..., Gatzoulis MA. Idiopathic pulmonary arterial hypertension and co-existing lung disease: is this a new phenotype? Pulm Circ. 2020 Mar 30;10(1):2045894020914851• Hoole SP, Coghlan JG, Cannon JE, et al. Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: the UK experience. Open Heart. 2020 Feb 27;7(1):e001144. doi: 10.1136/openhrt-2019-001144.• Kuwana M, Blair C, Takahashi T, Langley J, Coghlan JG. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis. Ann Rheum Dis. 2020 May;79(5):626-634. doi: 10.1136/annrheumdis-2019-216274.• Coghlan JG, Picken C, Clapp LH. Selexipag in the management of pulmonary arterial hypertension: an update. Drug Healthc Patient Saf. 2019 Aug 6;11:55-64.
...
All reviews are from real patients and have been verified by our Client Relations department to ensure they meet the service standards.
Patient reviews
J S. Verified Patient
02/09/2020
Would you recommend this doctor?
C G. Verified Patient
02/09/2020
Would you recommend this doctor?
M A. Verified Patient
17/03/2020
Would you recommend this doctor?
Patients comments
Yes, I would. Good explanations and interested.
L. Verified Patient
12/11/2018
Would you recommend this doctor?